Aadi Biosciences Inc AADI

NAS: AADI | ISIN: US00032Q1040   1/05/2025
1,670 USD (+12,84%)
(+12,84%)   1/05/2025

14 maart 2025 · Aadi Bioscience to Report Fourth Quarter and Full-Year 2024 Results and Corporate Update · Persbericht

4 maart 2025 · Aadi Bioscience Announces Closing of $100 Million PIPE Financing · Persbericht

3 maart 2025 · Aadi Bioscience Announces Approval of All Proposals at Special Meeting of Stockholders · Persbericht

20 augustus 2024 · Aadi Bioscience Provides PRECISION1 Trial and Corporate Updates · Persbericht

7 augustus 2024 · Aadi Bioscience Announces Financial Results for the Second Quarter 2024 and Provides Corporate Update · Persbericht

31 juli 2024 · Aadi Bioscience to Report Second Quarter 2024 Results and Corporate Update · Persbericht

29 mei 2024 · Aadi Bioscience to Participate in the Jefferies Healthcare Conference · Persbericht

23 mei 2024 · Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting · Persbericht

8 mei 2024 · Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update · Persbericht

1 mei 2024 · Aadi Bioscience to Report First Quarter 2024 Results and Corporate Update · Persbericht

9 april 2024 · Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting · Persbericht

17 maart 2024 · Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO) · Persbericht

13 maart 2024 · Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update · Persbericht

6 maart 2024 · Aadi Bioscience to Report Fourth Quarter and Full-Year 2023 Results and Corporate Update · Persbericht

5 maart 2024 · Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024 · Persbericht

1 maart 2024 · Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO® for the Treatment of Malignant PEComa · Persbericht

26 februari 2024 · Aadi Bioscience to Present at the TD Cowen 44th Annual Healthcare Conference · Persbericht

26 januari 2024 · Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium · Persbericht

19 januari 2024 · Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium · Persbericht

14 december 2023 · Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations · Persbericht

Mijn selecties